Table 1. Cold Agglutinin Disease Response Criteria.

Complete response Absence of anemia No signs of hemolysis Disappearance of clinical symptoms of CAD No monoclonal serum protein No signs of clonal lymphoproliferative disorder assessed by bone marrow biopsy, immunohistochemistry, and flow cytometry

Partial response A stable increase in Hgb by 2 g/dL or to normal range A reduction of serum IgM levels by at least 50% of the initial level or normal range Improvement of symptoms Transfusion independence

Note. CAD = cold agglutinin disease; Hbg = hemoglobin. Treatment response criteria for CAD trials evaluating rituximab monotherapy and combination therapy with bendamustine. Information from Röth et al. (2021); Khellaf et al. (2014)